There are 2 new Immunotherapy (without chemo) options for untreated metastatic NSCLC. We try to make sense of this evolving landscape.
Then, we run through the latest TKI, ripretinib. Finally, we discuss a new approval for Kaposi sarcoma and our obligatory PARP inhibitors update of the week.
Sep 25
SC Pembro, Biotin, 5-yr POLARIX data
The long awaited subcutaneous formulation of pembrolizumab is not FDA-approved. We discuss its administration and toxicity & PK differences vs. IV use. Biotin supplementation can interfere with lots of labs cancer patients get routinely - Who knew? (Ahem, not me.) Link: https://d ... Show More
18 m
Aug 14
11: Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma
The latest Oncology Decoded discussion with Manojkumar Bupathi, MD, MS, executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute (SCRI) and medical oncologist with Rocky Mountain Cancer Centers specializing in solid tumors and ... Show More
41m 45s
Nov 2024
ERS Monograph: COVID-19: An Update
"There isn't, and it is unlikely there ever will be, a single approach to long COVID. It's very much about personalised medicine."
James Chalmers steps away from the ERJ briefly to discuss the recent Monograph on "COVID-19: An Update", which he co-Guest Edited with Catia Cilloniz ... Show More
17m 48s
May 2025
Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell disease
In this week's episode, we’ll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesios ... Show More
19m 58s
Mar 2025
Lymphoma
Ninja Nerds,Welcome to the Ninja Nerd Podcast with Zach and Rob! In this episode, we dive deep into Lymphoma, breaking down its pathogenesis, clinical presentation, and the latest advancements in treatment. We explore the key differences between Hodgkin and Non-Hodgkin Lymphoma, ... Show More
34m 14s